T. Rowe Price reports 5.1% stake in Crinetics

T. Rowe Price Associates, Inc. filed an amendment reporting beneficial ownership of 5,355,011 shares of Crinetics Pharmaceuticals common stock, representing 5.1% of the class.

Rhea-AI Filing Summary

T. Rowe Price Associates, Inc. filed an amendment reporting beneficial ownership of 5,355,011 shares of Crinetics Pharmaceuticals common stock, representing 5.1% of the class. The filing lists sole voting power over 5,352,428 shares and sole dispositive power over 5,355,011 shares. The filing also includes a declarative statement denying beneficial ownership.

Insights

Institutional Ownership Analyst

Large passive holding reported: 5.1% stake in CRNX.

T. Rowe Price Associates, Inc. is shown holding 5,355,011 shares with sole voting and dispositive powers specified in the amendment. The position meets the technical Schedule 13G/A disclosure threshold for large passive investors.

Timing and trading intent are not stated; subsequent filings could clarify whether this is passive or active ownership.

Securities Compliance Counsel

Amendment documents ownership and includes an ownership denial clause.

The amendment records precise vote/dispositive counts and includes a sentence that the filer "expressly denied" beneficial ownership. That language is a filing-level assertion and may reflect internal attribution or contract structures.

Regulatory implications depend on the underlying arrangements; any change in status would trigger further reporting obligations.

Key Figures

Shares beneficially owned: 5,355,011 shares Percent of class: 5.1% Sole voting power: 5,352,428 shares +1 more

4 metrics

Shares beneficially owned 5,355,011 shares Amount beneficially owned reported in Schedule 13G/A

Percent of class 5.1% Percent of common stock class reported

Sole voting power 5,352,428 shares Sole power to vote reported

Sole dispositive power 5,355,011 shares Sole power to dispose reported

Key Terms

Schedule 13G/A, beneficial ownership, CUSIP

3 terms

Schedule 13G/A regulatory

"Amendment No. 1 ) CRINETICS PHARMACEUTICALS IN COMMON STOCK"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficial ownership regulatory

"Amount beneficially owned: 5355011 (b) Percent of class: 5.1 %"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

CUSIP financial

"CUSIP No.: 22663K107"

A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does T. Rowe Price report in CRNX?

T. Rowe Price reports 5,355,011 shares, representing 5.1% of Crinetics Pharmaceuticals common stock. The filing lists specific vote and dispositive power counts for that position.

How much voting power does T. Rowe Price have in Crinetics (CRNX)?

The filing shows sole voting power of 5,352,428 shares. Shared voting power is listed as 0, per the Schedule 13G/A amendment data provided in the excerpt.

Does the Schedule 13G/A amendment state T. Rowe Price is the beneficial owner?

No; the filing includes a declarative clause in which T. Rowe Price "expressly denied" being the beneficial owner of the securities referred to in the report.

What document identifies the security and CUSIP for this holding?

The Schedule 13G/A names the security as Common Stock of Crinetics Pharmaceuticals and gives the CUSIP 22663K107 in the filing excerpt.

When was the Schedule 13G/A signed?

The amendment is signed by Ellen York, Vice President, with a signature date of 05/15/2026 shown in the excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 10:07 AM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

CRINETICS PHARMACEUTICALS IN

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

22663K107

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 22663K107

1

Names of Reporting Persons

T. Rowe Price Associates, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 5,352,428.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,355,011.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,355,011.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: CRINETICS PHARMACEUTICALS IN
(b)	Address of issuer's principal executive offices: 10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO, CA, 92121
Item 2.
(a)	Name of person filing: T. Rowe Price Associates, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 22663K107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 5355011
(b)	Percent of class: 5.1 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 5352428
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 5355011
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Associates, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	05/15/2026